|
Volumn 15, Issue 3, 2002, Pages 283-287
|
Influenza vaccination for healthy children
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMANTADINE;
ANTIVIRUS AGENT;
INACTIVATED VACCINE;
INFLUENZA VACCINE;
LIVE VACCINE;
OSELTAMIVIR;
RIMANTADINE;
SIALIDASE INHIBITOR;
COST EFFECTIVENESS ANALYSIS;
DIAGNOSTIC PROCEDURE;
DRUG COST;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MANUFACTURE;
HUMAN;
IMMUNOGENICITY;
INFECTION PREVENTION;
INFECTION RISK;
INFLUENZA;
POPULATION DYNAMICS;
PUBLIC HEALTH SERVICE;
REVIEW;
RISK ASSESSMENT;
RISK FACTOR;
TREATMENT OUTCOME;
UNITED STATES;
VACCINATION;
VIRUS PATHOGENESIS;
|
EID: 0036100523
PISSN: 09517375
EISSN: None
Source Type: Journal
DOI: 10.1097/00001432-200206000-00011 Document Type: Review |
Times cited : (22)
|
References (32)
|